William Blair & Company
ACRS icon

William Blair & Company’s Aclaris Therapeutics ACRS Stock Holding History

William Blair & Company’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-12,800
Closed -$186K – 1906
2021
Q4 		$186K Buy
12,800
+2,750
+27% +$41.7K ﹤0.01% 1598
2021
Q3 		$181K Buy
+10,050
New +$161K ﹤0.01% 1519
2020
Q2 		– Sell
-10,600
Closed -$11K – 1675
2020
Q1 		$11K Sell
10,600
-8,072
-43% -$11K ﹤0.01% 1550
2019
Q4 		$35K Sell
18,672
-2,530
-12% -$4.19K ﹤0.01% 1524
2019
Q3 		$23K Sell
21,202
-39,180
-65% -$55.6K ﹤0.01% 1528
2019
Q2 		$132K Buy
60,382
+9,726
+19% +$53K ﹤0.01% 1387
2019
Q1 		$303K Sell
50,656
-6,072
-11% -$40.2K ﹤0.01% 1146
2018
Q4 		$419K Buy
56,728
+11,570
+26% +$119K ﹤0.01% 970
2018
Q3 		$656K Sell
45,158
-44,397
-50% -$761K ﹤0.01% 871
2018
Q2 		$1.79M Buy
89,555
+49,429
+123% +$913K 0.01% 581
2018
Q1 		$703K Sell
40,126
-5,321
-12% -$113K 0.01% 808
2017
Q4 		$1.12M Buy
45,447
+30,975
+214% +$754K 0.01% 715
2017
Q3 		$374K Buy
14,472
+797
+6% +$21.4K ﹤0.01% 1032
2017
Q2 		$371K Buy
+13,675
New +$372K ﹤0.01% 1091

Other funds holding ACRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

William Blair & Company's ACRS Position: Q1 2022 in Review

William Blair & Company sold out of Aclaris Therapeutics (ACRS) in Q1 2022, closing a stake of 12,800 shares — an estimated $186K sold.

William Blair & Company first reported a position in ACRS in Q2 2017 and held it in 14 quarters. The position peaked at $1.79M in Q2 2018. 109 funds tracked by Wall St. Rank hold ACRS as of Q1 2022.

  • William Blair & Company reported no remaining Aclaris Therapeutics position as of Q1 2022 after selling out during the quarter.
  • William Blair & Company sold 12,800 Aclaris Therapeutics shares in Q1 2022, an estimated $186K.
  • William Blair & Company first reported a position in Aclaris Therapeutics in Q2 2017 and held it in 14 quarters.
  • William Blair & Company's Aclaris Therapeutics position peaked at $1.79M in Q2 2018.
  • 109 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2022.

Based on William Blair & Company's 13F filing for Q1 2022, filed 13 May 2022.